|
Volume 11 Issue 5
|
|
Comment |
|
|
Development of 'synthetic lethal' strategies to target BRCA1-deficient breast cancer
Max S Wicha Breast Cancer Research 2009, 11:108 (23 September 2009)
Abstract | Full text | PDF | PubMed | Cited on BioMed Central
|
|
|
Circulating tumor cells in blood of primary breast cancer patients assessed by a novel RT-PCR test kit and comparison with status of bone marrow-disseminated tumor cells
Manfred Schmitt, John A Foekens Breast Cancer Research 2009, 11:109 (9 October 2009)
Abstract | Full text | PDF | PubMed
|
|
|
Notch versus the proteasome: what is the target of γ-secretase inhibitor-I?
Anthony G Clementz, Clodia Osipo Breast Cancer Research 2009, 11:110 (15 October 2009)
Abstract | Full text | PDF | PubMed
|
|
|
Physical activity and breast cancer survival
Adeyemi A Ogunleye, Michelle D Holmes Breast Cancer Research 2009, 11:106 (1 September 2009)
Abstract | Full text | PDF | PubMed
|
|
Review |
|
|
Key signalling nodes in mammary gland development and cancer. Mitogen-activated protein kinase signalling in experimental models of breast cancer progression and in mammary gland development
Jacqueline Whyte, Orla Bergin, Alessandro Bianchi, Sara McNally, Finian Martin Breast Cancer Research 2009, 11:209 (29 September 2009)
Abstract | Full text | PDF | PubMed | Cited on BioMed Central
|
|
|
Key signalling nodes in mammary gland development and cancer: Myc
Nancy E Hynes, Tina Stoelzle Breast Cancer Research 2009, 11:210 (15 October 2009)
Abstract | Full text | PDF | PubMed | Cited on BioMed Central
|
|
|
Update on the use of aromatase inhibitors in early-stage breast cancer
Georgios Kesisis, Andreas Makris, David Miles Breast Cancer Research 2009, 11:211 (28 October 2009)
Abstract | Full text | PDF | PubMed
|
|
|
Androgens and the breast
Constantine Dimitrakakis, Carolyn Bondy Breast Cancer Research 2009, 11:212 (30 October 2009)
Abstract | Full text | PDF | PubMed | Cited on BioMed Central
|
|
Report |
|
|
Correction: Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes
Olafur Stefansson, Jon Jonasson, Oskar Johannsson, Kristrun Olafsdottir, Margret Steinarsdottir, Sigridur Valgeirsdottir, Jorunn Eyfjord Breast Cancer Research 2009, 11:404 (2 September 2009)
Full text | PDF | PubMed
|
|
Research |
|
|
Magnetic resonance imaging of the natural history of in situ mammary neoplasia in transgenic mice: a pilot study
Sanaz A Jansen, Suzanne D Conzen, Xiaobing Fan, Erica J Markiewicz, Gillian M Newstead, Gregory S Karczmar Breast Cancer Research 2009, 11:R65 (4 September 2009)
Abstract | Full text | PDF | PubMed
|
|
|
An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ
Fariba Behbod, Frances S Kittrell, Heather LaMarca, David Edwards, Sofia Kerbawy, Jessica C Heestand, Evelin Young, Purna Mukhopadhyay, Hung-Wen Yeh, D Craig Allred, Min Hu, Kornelia Polyak, Jeffrey M Rosen, Daniel Medina Breast Cancer Research 2009, 11:R66 (7 September 2009)
Abstract | Full text | PDF | PubMed
|
|
|
Steroid Receptor RNA Activator Protein (SRAP): a potential new prognostic marker for estrogen receptor-positive/node-negative/younger breast cancer patients
Yi Yan, George P Skliris, Carla Penner, Shilpa Chooniedass-Kothari, Charlton Cooper, Zoann Nugent, Anne Blanchard, Peter H Watson, Yvonne Myal, Leigh C Murphy, Etienne Leygue Breast Cancer Research 2009, 11:R67 (9 September 2009)
Abstract | Full text | PDF | PubMed
|
Editor’s summary
Steroid receptor RNA activator protein(SRAP) levels are associated with poor survival in ER positive, node-negative, younger breast cancer patients, and could be potential prognosis/predictive markers in this subset.
|
|
|
Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-β signaling and metastasis
Michael K Wendt, William P Schiemann Breast Cancer Research 2009, 11:R68 (9 September 2009)
Abstract | Full text | PDF | PubMed | Cited on BioMed Central
|
|
|
Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy
Silvia Darb-Esfahani, Sibylle Loibl, Berit M Müller, Marc Roller, Carsten Denkert, Martina Komor, Karsten Schlüns, Jens Uwe Blohmer, Jan Budczies, Bernd Gerber, Aurelia Noske, Andreas du Bois, Wilko Weichert, Christian Jackisch, Manfred Dietel, Klaus Richter, Manfred Kaufmann, Gunter von Minckwitz Breast Cancer Research 2009, 11:R69 (16 September 2009)
Abstract | Full text | PDF | PubMed | Cited on BioMed Central
|
|
|
The membrane mucin MUC4 is elevated in breast tumor lymph node metastases relative to matched primary tumors and confers aggressive properties to breast cancer cells
Heather C Workman, Jamie K Miller, Ellen Q Ingalla, Rouminder P Kaur, Diane I Yamamoto, Laurel A Beckett, Lawrence JT Young, Robert D Cardiff, Alexander D Borowsky, Kermit L Carraway, Colleen Sweeney, Kermit L Carraway Breast Cancer Research 2009, 11:R70 (18 September 2009)
Abstract | Full text | PDF | PubMed
|
Editor’s summary
The membrane mucin, MUC4, is re-expressed during breast cancer progression and enhances malignancy by promoting the survival and proliferation of non-adherent actively metastizing cells.
|
|
|
Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer
Heidi Schwarzenbach, Klaus Pantel, Birthe Kemper, Cord Beeger, Friedrich Otterbach, Rainer Kimmig, Sabine Kasimir-Bauer Breast Cancer Research 2009, 11:R71 (21 September 2009)
Abstract | Full text | PDF | PubMed | Cited on BioMed Central
|
|
|
Estrogen and progesterone receptors have distinct roles in the establishment of the hyperplastic phenotype in PR-A transgenic mice
Marina Simian, Mina J Bissell, Mary Barcellos-Hoff, Gopalan Shyamala Breast Cancer Research 2009, 11:R72 (29 September 2009)
Abstract | Full text | PDF | PubMed
|
|
|
Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer
Mark D Pegram, Virginia F Borges, Nuhad Ibrahim, Jyotsna Fuloria, Charles Shapiro, Susan Perez, Karen Wang, Franziska Schaedli Stark, Nigel Courtenay Luck Breast Cancer Research 2009, 11:R73 (7 October 2009)
Abstract | Full text | PDF | PubMed
|
|
|
BU-32: a novel proteasome inhibitor for breast cancer
Joseph K Agyin, Bindu Santhamma, Hareesh B Nair, Sudipa S Roy, Rajeshwar R Tekmal Breast Cancer Research 2009, 11:R74 (12 October 2009)
Abstract | Full text | PDF | PubMed
|
Editor’s summary
The novel proteasome inhibitor, BU-32, exhibits strong cytotoxic and growth inhibitory effects in cultured cell lines and xenografts, pointing to its potential use as a breast cancer treatment.
|
|
|
Distinct inherited metastasis susceptibility exists for different breast cancer subtypes: a prognosis study
Szu-Min Hsieh, Maxime P Look, Anieta M Sieuwerts, John A Foekens, Kent W Hunter Breast Cancer Research 2009, 11:R75 (13 October 2009)
Abstract | Full text | PDF | PubMed | Cited on BioMed Central
|
|
|
Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers
Susan L Neuhausen, Sean Brummel, Yuan Ding, Christian F Singer, Georg Pfeiler, Henry T Lynch, Katherine L Nathanson, Timothy R Rebbeck, Judy E Garber, Fergus Couch, Jeffrey Weitzel, Steven A Narod, Patricia A Ganz, Mary B Daly, Andrew K Godwin, Claudine Isaacs, Olufunmilayo I Olopade, Gail Tomlinson, Wendy S Rubinstein, Nadine Tung, Joanne L Blum, Daniel L Gillen Breast Cancer Research 2009, 11:R76 (20 October 2009)
Abstract | Full text | PDF | PubMed
|
|
|
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
Richard S Finn, Judy Dering, Dylan Conklin, Ondrej Kalous, David J Cohen, Amrita J Desai, Charles Ginther, Mohammad Atefi, Isan Chen, Camilla Fowst, Gerret Los, Dennis J Slamon Breast Cancer Research 2009, 11:R77 (29 October 2009)
Abstract | Full text | PDF | PubMed | Cited on BioMed Central
|
